Analysts Anticipate Genomic Health, Inc. (GHDX) to Post $0.29 Earnings Per Share
Equities analysts expect that Genomic Health, Inc. (NASDAQ:GHDX) will announce earnings of $0.29 per share for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Genomic Health’s earnings. The lowest EPS estimate is $0.26 and the highest is $0.30. Genomic Health posted earnings of $0.13 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 123.1%. The firm is scheduled to announce its next earnings results on Wednesday, May 1st.
On average, analysts expect that Genomic Health will report full-year earnings of $1.49 per share for the current financial year, with EPS estimates ranging from $1.42 to $1.54. For the next fiscal year, analysts forecast that the business will report earnings of $1.67 per share, with EPS estimates ranging from $1.43 to $1.85. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Genomic Health.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Wednesday, February 20th. The medical research company reported $0.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.02. The business had revenue of $104.56 million during the quarter, compared to the consensus estimate of $101.55 million. Genomic Health had a net margin of 6.52% and a return on equity of 16.86%. Genomic Health’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 earnings per share.
In other news, Director Bros. Advisors Lp Baker sold 600 shares of the business’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $76.20, for a total value of $45,720.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO G Bradley Cole sold 15,000 shares of the business’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $67.61, for a total transaction of $1,014,150.00. The disclosure for this sale can be found here. In the last three months, insiders sold 2,246,252 shares of company stock worth $163,036,665. 45.80% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in GHDX. Wells Fargo & Company MN lifted its position in shares of Genomic Health by 3.7% in the third quarter. Wells Fargo & Company MN now owns 57,324 shares of the medical research company’s stock worth $4,025,000 after purchasing an additional 2,071 shares in the last quarter. JPMorgan Chase & Co. raised its position in Genomic Health by 15.2% during the third quarter. JPMorgan Chase & Co. now owns 6,145 shares of the medical research company’s stock worth $432,000 after acquiring an additional 813 shares in the last quarter. BlackRock Inc. raised its position in Genomic Health by 1.7% during the third quarter. BlackRock Inc. now owns 2,037,436 shares of the medical research company’s stock worth $143,070,000 after acquiring an additional 34,464 shares in the last quarter. FMR LLC raised its position in Genomic Health by 125.5% during the third quarter. FMR LLC now owns 299,542 shares of the medical research company’s stock worth $21,034,000 after acquiring an additional 166,681 shares in the last quarter. Finally, United Services Automobile Association bought a new stake in Genomic Health during the third quarter worth $440,000. 90.60% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ GHDX opened at $61.93 on Monday. The company has a market cap of $2.29 billion, a P/E ratio of 58.98 and a beta of 0.95. Genomic Health has a 52-week low of $31.05 and a 52-week high of $92.18.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Read More: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.